Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women over 18~* Tissue diagnosis of metastatic colon cancer without operational or radiation therapy options~* No RAS mutation in tumor tissue~* Measurable disease according to RACIST criteria v1.1~* ECOG ( Eastern Cooperative Oncology Group) performance status \<=2~* Life expectancy of over 3 months~* Women of fertility age not pregnant~* Ability to understand and sign and informed consent form to participate in the trial and the ability to perform the treatment and follow up required for participation in the trial~* At least three months progression free time in first line cetuximab treatment~* Disease progression according to RACIST v1.1 for first and second lines~* Third line treatment will be applied no less then 17 weeks following and of first line treatment~Exclusion Criteria:~* RAS mutation carriers, or patients with uncertain metastatic colon cancer diagnosis~* Patients operated two weeks prior to accepting trail drug, or that did not recover from treatment~* Level 3 allergic response to any of trial drugs~* First line cetuximab treatment stopped due to allergic response~* Severe medical or mental diagnosis which might increase the risk in drug administration according to treating physician's discretion~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Metastatic colorectal cancer patients (Type: EXPERIMENTAL): Metastatic colorectal cancer patients receiving third line cetuximab treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).